CSL 112

Drug Profile

CSL 112

Alternative Names: Apolipoprotein A-I - CSL Behring; CSL-112; CSL112 (reconstituted HDL) - CSL; CSL112 apo-AI; rHDL - CSL

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL
  • Class Antihyperlipidaemics; Cardiovascular therapies; Lipoproteins
  • Mechanism of Action Cholesterol modulators; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myocardial infarction
  • Phase II Atherosclerosis

Most Recent Events

  • 16 May 2018 CSL Limited initiates enrolment in a phase I pharmacokinetics trial in healthy volunteers in Australia (IV) (ACTRN12618000805279)
  • 12 May 2018 CSL Limited plans a phase I trial for Coronary heart disease (In volunteers) in Australia , (ACTRN12618000805279)
  • 23 Mar 2018 Phase-III clinical trials in Myocardial infarction in USA (IV) (NCT03473223)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top